BIOHIT OYJ STOCK EXCHANGE RELEASE, 29 AUGUST 2008 AT 2:45 PM BIOHIT'S CO-DETERMINATION NEGOTIATIONS HAVE ENDED In June 2008, Biohit launched co-determination negotiations as part of its measures to improve profitability. These negotiations ended today, and the company has decided to implement its planned personnel cost savings with lay-offs. The measures will affect both Biohit personnel and leased employees: Biohit will temporarily reduce the number of leased employees by ten and lay off ten of its own employees. The personnel reductions will primarily affect those working for the parent company in the diagnostics business or in production and logistics in the liquid handling business. Some of the lay-offs will be implemented using part-time employment contracts. Lay-offs will begin in September and remain in force until further notice. At the beginning of June, Biohit launched a savings and operational efficiency programme to improve the profitability of the entire group. The estimated need for lay-offs was 21 employees. Biohit is also reducing other fixed costs both in the parent company and subsidiaries. The company will continue to develop the diagnostics business in spite of the personnel reductions. Osmo Suovaniemi President and CEO Biohit Oyj Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 GSM: +358-40-745 5605 E-mail: osmo.suovaniemi@biohit.com Distribution: Helsinki Stock Exchange Central storage facility (www.oam.fi) Principal media www.biohit.com About Biohit Oyj: Biohit Oyj is a Finnish company that develops, manufactures and markets liquid handling products and diagnostic tests and analysis systems for use in research, healthcare and industrial laboratories. The liquid handling range includes electronic and mechanical pipettes, disposable tips, and pipette maintenance and calibration services. The diagnostics business comprises products and analysis systems for the diagnosis, screening and prevention of gastrointestinal diseases (such as the blood sample based GastroPanel and GastroView for diagnosing diseases of the stomach and associated risks, as well as quick tests for the diagnosis of lactose intolerance and H. pylori infection). Approximately 370 people work for the Biohit Group in eight countries. Biohit Oyj is headquartered in Helsinki, Finland. The company has subsidiaries in France, Germany, the UK, Russia, China, Japan and the USA. Biohit's products are also sold by approximately 450 distributors in 70 countries. Biohit Oyj's series B shares are quoted on the Helsinki Stock Exchange (OMX Nordic Exchange Helsinki) in the Small cap/Healthcare group under the code BIOBV. Read more at www.biohit.com